Bottom Line: For children and adults with food allergies, personal self-injectable epinephrine devices are crucial to treating severe reactions such as anaphylaxis if there is unintended exposure to allergens. Autoinjectors have become very expensive, although the drug they inject is cheap. In this study of simulated children with peanut allergy, researchers estimated value-based pricing for the devices, which is a method of drug pricing where drug costs are based on the magnitude of the benefit they provide. This analysis suggests a value-based pricing model for autoinjectors at no more than $24 a year for children with peanut allergies to protect against risk of death.
Authors: Marcus Shaker, M.D., M.S., Dartmouth Geisel School of Medicine, Lebanon, New Hampshire, and Matthew Greenhawt, M.D., M.B.A., M.Sc., University of Colorado School of Medicine, Aurora, Colorado
###
To Learn More: The full study is available on the For The Media website.
(doi:10.1001/jamanetworkopen.2018.4728)
Editor's Note: The article contains conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Want to embed a link to this study in your story?: Links will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2018.4728
About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. Every Friday, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open